University of Cambridge > Talks.cam > Cambridge Oncology Seminar Series > Interactions of Epidermal Growth Factor Receptor Inhibition with DNA damage in the treatment of gastrointestinal cancer

Interactions of Epidermal Growth Factor Receptor Inhibition with DNA damage in the treatment of gastrointestinal cancer

Add to your list(s) Download to your calendar using vCal

  • UserProf Daniel Hochhauser, University College London
  • ClockTuesday 14 September 2010, 12:00-13:00
  • HouseCRI Lecture Theatre.

If you have a question about this talk, please contact Mala Jayasundera.

There has been extensive development of targeted therapies for treatment of cancer. These include antibodies and small molecules which inhibit pathways essential for cancer cell proliferation and metastasis. An important example is the epidermal growth factor receptor (EGFR) pathway which is the target of antibodies (cetuximab, panitumumab) and small molecules (gefitinib, erlotinib) used clinically. Although specific EGFR mutations found in lung cancer result in significant sensitivity to gefitinib and erlotinib, the response to single agents has been modest. Preclinical evaluation has suggested synergy between chemotherapy and radiation when combined with EGFR inhibition. However this has not generally translated into clinical benefit. In this presentation the possible mechanisms of these interactions will be outlined, together with suggestions for design of optimal combinations of EGFR inhibitors and chemotherapy, using gastrointestinal cancer as an example.

This talk is part of the Cambridge Oncology Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2019 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity